Logo - springer
Slogan - springer

Medicine - Oncology & Hematology | Targeted Therapeutics in Melanoma

Targeted Therapeutics in Melanoma

Gajewski, Thomas F., Hodi, F. Stephen (Eds.)

2012, XIV, 378 p.

A product of Humana Press
Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$169.00

(net) price for USA

ISBN 978-1-61779-407-0

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$219.00

(net) price for USA

ISBN 978-1-61779-406-3

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$219.00

(net) price for USA

ISBN 978-1-62703-876-8

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

  • Describes both established signal transduction inhibitors as well as emerging molecularly-guided immunotherapies
  • Places exciting developments in basic biological understanding into a practical clinical context
  • The first book on melanoma devoted entirely to targeted therapeutics
  • Includes the most up-to-date data from current clinical Phase I-III trials
  • Written by high-profile authors representing the world’s leaders in their field

Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging.

The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.

This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.

Content Level » Research

Keywords » B-Raf - CTLA-4 - Immunotherapy - Melanoma - Molecularly-guided Immunotherapies - PD-1 - Signal Transduction Inhibitors - Skin Cancer - Targeted Therapy - c-kit - mAbs

Related subjects » Cancer Research - Oncology & Hematology

Table of contents / Preface / Sample pages 

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Oncology.